Mitchell Finer, PhD, a scientist with expertise in biochemistry and molecular biology, who has had an integral role in the success of numerous biotechnology companies, including most recently as chief scientific officer of gene therapy innovator bluebird bio, shares insights on his experiences and what it takes to shepherd a biotech start-up to commercial success in an interview recently published in Human Gene Therapy Clinical Development , a peer-reviewed journal from Mary Ann Liebert, Inc., publishers . The article is available free on the Human Gene Therapy Clinical Development website until November 22, 2015.